Description
CC-671 is a dual TTK/CLK2 inhibitor. It acts by inhibiting the phosphorylation of KNL1 and SRp75, direct substrates of TTK and CLK2. It is a monotherapy candidate for treatment of triple negative breast cancer.
Product Unit Size | Cost | Quantity | Stock |
---|
CC-671 is a dual TTK/CLK2 inhibitor. It acts by inhibiting the phosphorylation of KNL1 and SRp75, direct substrates of TTK and CLK2. It is a monotherapy candidate for treatment of triple negative breast cancer.
Cas No. | 1618658-88-0 |
---|---|
Purity | ≥98% |
Formula | C28H28N6O4 |
Formula Wt. | 512.57 |
IUPAC Name | 4-{[4-(Cyclopentyloxy)-5-(2-methyl-1,3-benzoxazol-6-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-yl]amino}-3-methoxy-N-methylbenzamide |
Synonym | CC 671, CC671 |
Store Temp | -20°C |
---|---|
Ship Temp | Ambient |
MSDS | |
---|---|
Info Sheet |
Riggs J., Nagy M., et al. The Discovery of a Dual TTK Protein Kinase/CDC2-Like Kinase (CLK2) Inhibitor for the Treatment of Triple Negative Breast Cancer Initiated from a Phenotypic Screen. J Med Chem. 60(21):8989-9002 (2017). PMID: 28991472.
Zhu D., Xu S., et al. Synthetic Lethal Strategy Identifies a Potent and Selective TTK and CLK1/2 Inhibitor for Treatment of Triple-Negative Breast Cancer with a Compromised G1-S Checkpoint. Mol Cancer Ther. 17(8):1727-38 (2018). PMID: 29866747.
Phenol found in Zingiber; 5-HT3 antagonist.
p110δ PI3K inhibitor.
Macrolide; protein translation inhibitor.
Phenylethylamine; β2-adrenergic agonist, SK/BK...
JAK1 inhibitor.
DPP4 inhibitor.
Toll-like receptor 7/8 agonist
Synthesis impurity
STING antagonist
Glycosylated isoflavone found in soy; TAS2R ago...
Non-competitive inhibitor of xanthine oxidase.<...
Furocoumarin; COX-2 inhibitor.
HIV protease inhibitor.
Abl inhibitor.
Selective cannabinoid receptor 2 (CB2) inverse ...
Diterpene found in brewed, unfiltered coffee; F...
Sirtuin inhibitor and iron chelator.
May induce apoptosis in lymphoma cell lines.
Endogenous amino acid, forms disulfide bridges ...
Endogenous peptide hormone, involved in feeding...